## Ravicti (glycerol phenylbutyrate) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENT		
MEMBER INFORMATION					
LAST NAME:		FIRST NAME:			
PHONE NUMBER:		DATE OF BIRTH:			
STREET ADDRESS:					
CITY:		STATE: ZIP CODE:			
PATIENT INSURANCE ID NUM	MBER:				
MALE FEMALE HEIG					
FOLLOWING LINK: PRIMETHERAPEUTICS.COM,	/NOPP				
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):					
AUTHORIZED REPRESENTATIV	/E'S PHONE NUMBER:				
PRESCRIBER INFORMATION					
LAST NAME:		FIRST NAME:			
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:			
NPI NUMBER:		DEA NUMBER:			
PHONE NUMBER:		FAX NUMBER:			
STREET ADDRESS:					
CITY:		STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:			
MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
☐ NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:			
DURATION OF THERAPY (SPE	CIFIC DATES):				

Continued on next page.



## Ravicti (glycerol phenylbutyrate) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTH	ER MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO	
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
☐ Urea cycle disorders (UCD)☐ Other diagnosis:	ICD-10:		
<b>3. REQUIRED CLINICAL INFORMATION</b> PRIOR AUTHORIZATION.	N: PLEASE PROVIDE ALL RELEVANT CLINIC	CAL INFORMATION TO SUPPORT A	
Clinical Information:			
Will patient be using drug in combina	ation with a clinical trial?		
Is the prescriber a specialist in urea of	ycle disorders and/or a geneticist?		
Does the patient have a diagnosis of chart documentation supporting this	a urea cycle disorder with hyperammon information	emia? □ Yes □ No *Please provide	
	n tried and found inadequate in control Please provide chart documentation sup	_ ,	
Will the patient continue to be on pr	otein restrictions while taking Ravicti?	Yes □ No	
Has patient had a previous trial and to provide chart documentation.	failure with sodium phenylbutrate(gene	ric Buphenyl) ?*□ Yes □ No *Please	
Renewal Criteria: Is patient continuing to demonstrate documentation supporting this information.	a positive clinical response?   Yes Oncome	*Please provide chart	
Is the patient continuing to adhere to supporting this information.	o a protein restrictive diet?   Yes   No	*Please provide chart documentation	
Are there any other comments, diagonal physician feels is important to this re	noses, symptoms, medications tried or faview?	ailed, and/or any other information the	
Please note: Not all drugs/diagnosis a information is received.	are covered on all plans. This request may	be denied unless all required	
the Health Plan, insurer, Medical Gro	on provided is true and accurate to the be up or its designees may perform a routine ccuracy of the information reported on th	e audit and request the medical	
Prescriber Signature or Electronic I.D	. Verification:	Date:	



## Ravicti (glycerol phenylbutyrate) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

**CONFIDENTIALITY NOTICE:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

**FAX THIS FORM TO: 800-424-7640** 

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

